News | November 14, 2014

Boston Scientific Subcutaneous ICD Receives Favorable AMA Coding, Payment Designations

New CPT Category I code facilitates processing for U.S. hospitals and physicians


November 14, 2014 — Boston Scientific Corp. announced that its subcutaneous implantable defibrillator (S-ICD System) will have designated Current Procedural Terminology (CPT) Category I codes by the American Medical Association (AMA), effective Jan. 1, 2015. The AMA CPT coding system provides United States physicians and hospitals with a uniform process for coding medical services. By definition, the CPT I category includes procedures that are widely performed and consistent with contemporary medical practice.

Also effective Jan. 1, 2015, the Medicare hospital outpatient payment rate for implanting the S-ICD System will increase by 23 percent. Additionally, Aetna recently joined several other private health plans by broadening its coverage for the S-ICD System to all patients who meet the criteria for an ICD and are not contraindicated.

"The S-ICD System is an advanced, less invasive option for patients at risk of sudden cardiac arrest," said Michael Gold, professor of medicine and director of cardiology, Medical University of South Carolina. "The new CPT categorization establishes more predictable coding processes for hospitals and physicians when implanting the S-ICD System. This change should improve patient access to this important therapy."

The S-ICD System may offer certain groups of patients an alternative to more invasive transvenous ICDs. As the world's least invasive implantable defibrillator, the S-ICD System provides protection for patients at risk of sudden cardiac arrest while leaving the heart and blood vessels untouched.

For more information: www.bostonscientific.com


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely ...

Home February 12, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 23, 2023 — Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug ...

Home October 23, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Medtronic ICDs and CRT-Ds ...

Home July 18, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no ...

Home March 07, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

Home February 17, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 18, 2022 — A first-in-human multicenter trial involving Mayo Clinic used a new ablation technique for patients ...

Home August 18, 2022
Home
Subscribe Now